You just read:

(Pr)Lucentis® (ranibizumab) approved by Health Canada to treat vision loss resulting from choroidal neovascularization in pathologic myopia (mCNV)(1)

News provided by

Novartis Pharmaceuticals Canada Inc.

Oct 08, 2014, 08:00 ET